Retina/Vitreous News

NEW ORLEANS — An investigational device that measures ocular oxygen saturation may help detect disease earlier and potentially preserve sight, according to a presenter at the Academy ’23 Innovations in Vision and Eye Care program.

NEW YORK — In this Healio Video Perspective from OSN New York Retina, Aleksandra Rachitskaya, MD, overviews three studies investigating diabetic macular edema from the DRCR Retina Network.

In the phase 3 BALATON and COMINO studies, Vabysmo demonstrated vision maintenance and anatomic improvements up to week 72 in macular edema secondary to retinal vein occlusion, or RVO, according to a Genentech press release.

Ultra-widefield imaging alone is not sufficient for detecting retinal horseshoe tears and should not replace funduscopic examination, according to a study published in the American Journal of Ophthalmology.

Pregnant women with a history of retinal detachment were at no greater risk for recurrence after vaginal delivery compared with cesarean section, according to a study published in Retina.

LAS VEGAS — Optos has expanded the optomap retinal imaging capabilities for its California FA device, which now includes an ultra-widefield red/green/blue image, the company announced at Vision Expo West.

The complement component 5 inhibitor avacincaptad pegol may have potential as a treatment to reduce geographic atrophy lesion growth and slow progression of disease, according to a study published in The Lancet.

An 80-year-old white male presented to the eye clinic for a recent-onset visual disturbance. The patient reported that there was a large, black spot in the central vision of his right eye. He first noticed the dark spot the previous day and described his vision as being blurry. He denied any ocular pain or new onset of flashes or floaters.

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Dante J. Pieramici, MD, overviews pharmacokinetics and safety data for sozinibercept.

Patients with wet age-related macular degeneration who were switched from aflibercept alone to a combination of aflibercept and UBX1325 at week 24 maintained vision gains through 48 weeks in part B of the phase 2 ENVISION study.